Literature DB >> 15920519

Mining for regulatory programs in the cancer transcriptome.

Daniel R Rhodes1, Shanker Kalyana-Sundaram, Vasudeva Mahavisno, Terrence R Barrette, Debashis Ghosh, Arul M Chinnaiyan.   

Abstract

DNA microarrays have been widely applied to cancer transcriptome analysis. The Oncomine database contains a large collection of such data, as well as hundreds of derived gene-expression signatures. We studied the regulatory mechanisms responsible for gene deregulation in these cancer signatures by searching for the coordinate regulation of genes with common transcription factor binding sites. We found that genes with binding sites for the archetypal cancer transcription factor, E2F, were disproportionately overexpressed in a wide variety of cancers, whereas genes with binding sites for other transcription factors, such as Myc-Max, c-Rel and ATF, were disproportionately overexpressed in specific cancer types. These results suggest that alterations in pathways activating these transcription factors may be responsible for the observed gene deregulation and cancer pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15920519     DOI: 10.1038/ng1578

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  84 in total

1.  A genome-wide RNA interference screen identifies putative chromatin regulators essential for E2F repression.

Authors:  Jianrong Lu; Marie-Laure Ruhf; Norbert Perrimon; Philip Leder
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-17       Impact factor: 11.205

2.  Systematic functional characterization of cis-regulatory motifs in human core promoters.

Authors:  Saurabh Sinha; Adam S Adler; Yair Field; Howard Y Chang; Eran Segal
Journal:  Genome Res       Date:  2008-02-06       Impact factor: 9.043

3.  BAFF-R promotes cell proliferation and survival through interaction with IKKbeta and NF-kappaB/c-Rel in the nucleus of normal and neoplastic B-lymphoid cells.

Authors:  Lingchen Fu; Yen-Chiu Lin-Lee; Lan V Pham; Archito T Tamayo; Linda C Yoshimura; Richard J Ford
Journal:  Blood       Date:  2009-03-03       Impact factor: 22.113

4.  Control of alveolar differentiation by the lineage transcription factors GATA6 and HOPX inhibits lung adenocarcinoma metastasis.

Authors:  William K C Cheung; Minghui Zhao; Zongzhi Liu; Laura E Stevens; Paul D Cao; Justin E Fang; Thomas F Westbrook; Don X Nguyen
Journal:  Cancer Cell       Date:  2013-05-23       Impact factor: 31.743

Review 5.  Insights to transcriptional networks by using high throughput RNAi strategies.

Authors:  Jaakko Mattila; Oscar Puig
Journal:  Brief Funct Genomics       Date:  2009-12-01       Impact factor: 4.241

6.  Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling.

Authors:  Thomas J Giordano; Rork Kuick; Tobias Else; Paul G Gauger; Michelle Vinco; Juliane Bauersfeld; Donita Sanders; Dafydd G Thomas; Gerard Doherty; Gary Hammer
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

Review 7.  Recurrent gene fusions in prostate cancer.

Authors:  Chandan Kumar-Sinha; Scott A Tomlins; Arul M Chinnaiyan
Journal:  Nat Rev Cancer       Date:  2008-06-19       Impact factor: 60.716

8.  Regulatory potential for concerted modulation of Nrf2- and Nfkb1-mediated gene expression in inflammation and carcinogenesis.

Authors:  S Nair; S T Doh; J Y Chan; A-N Kong; L Cai
Journal:  Br J Cancer       Date:  2008-12-02       Impact factor: 7.640

9.  Overexpression of an activated REL mutant enhances the transformed state of the human B-lymphoma BJAB cell line and alters its gene expression profile.

Authors:  M Chin; M Herscovitch; N Zhang; D J Waxman; T D Gilmore
Journal:  Oncogene       Date:  2009-04-20       Impact factor: 9.867

10.  Identification of cell cycle-related regulatory motifs using a kernel canonical correlation analysis.

Authors:  Je-Keun Rhee; Je-Gun Joung; Jeong-Ho Chang; Zhangjun Fei; Byoung-Tak Zhang
Journal:  BMC Genomics       Date:  2009-12-03       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.